Africa: What It Would Take to Get Super-Cold Covid-19 Vaccine to West Africa

Pfizer World Headquarters in New York City.

Dakar — A promising new coronavirus vaccine must be kept at Antarctic temperatures, raising concerns for delivery in Africa

Hope is rising that a new vaccine could halt the COVID-19 pandemic - for some - but lessons learnt from past vaccine programmes in West Africa suggest millions more might miss out.

The super-cold storage temperature required for the new vaccine will make it near impossible to deliver in rural parts of Africa, said public health expert Evelyn Castle.

"We would need all new infrastructure," said Castle, executive director of the Nigeria-based non-profit organisation eHealth Africa, which in 2016 helped distribute an Ebola vaccine in Sierra Leone at similar temperatures.

"(In Sierra Leone), we had to do full renovations of some of the facilities we worked in."

The pharmaceutical company Pfizer and its partner BioNTech SE said on Monday that initial trials showed their experimental COVID-19 vaccine was more than 90% effective.

But the vaccine must be kept at temperatures of minus 70 degrees Celsius (-94 F) or below - colder than the North Pole. Even sophisticated U.S. hospitals say they lack that capability.

Routine vaccines typically need to be stored at 2-8°C, about the temperature of a normal refrigerator, and even this is a challenge for much of West Africa, where electricity is non-existent or unreliable, said Castle.

The Ebola vaccine trial in Sierra Leone involved immunising about 8,000 health workers - quite a task, but nothing compared to the job of protecting millions against COVID-19, said Castle.

Coronavirus has killed almost 1.3 million people worldwide and infected 50 million. European nations have already started making deals with Pfizer to purchase millions of doses of the vaccine.

Other companies including Moderna Inc , Johnson & Johnson and Novavax Inc are working on developing vaccines that would not need such low temperatures.

But the first out the block, if it wins emergency U.S. approval as hoped this month, would be Pfizer's, ensuring a global scramble for infrastructure to make it work.


In Nigeria, many rural health centres have solar-powered fridges, but Castle said they lack the power to hit -70°C.

Generators would be needed, along with someone to ensure they were serviced, fuelled, and monitored constantly so they didn't drop below the temperature threshold, she said.

Transportation would also be challenging, and not just because of temperature constraints.

"Obviously there are a lot of challenges with keeping it cold in transport, but you might not even have cars, you might not have fuel, you might not have drivers to do the actual delivery," she said.

In Sierra Leone, health centres had to be equipped with running water so the Ebola vaccine could be administered safely, and with internet to keep track of patient records.

Given all this, a likely scenario is that any vaccine would go to urban areas first, Castle said - in itself a potential problem.

"If we have a limited number of vaccines, who are we going to target? Are we really just going to be giving this to the rich people living in cities?"

More From: Thomson Reuters Foundation

AllAfrica publishes around 800 reports a day from more than 130 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.